Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease

American Heart Journal

Volumn 166, Issue 2, 2013, Pages

  Böhm, Michael ^a   Schumacher, Helmut ^b   Laufs, Ulrich ^a   Sleight, Peter ^c   Schmieder, Roland ^d   Unger, Thomas ^e   Teo, Koon ^f   Yusuf, Salim ^f  

^a SAARLAND UNIVERSITY   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL; TELMISARTAN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GENDER; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT REFUSAL;

EID: 84880922378     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.04.016     Document Type: Article

References (30)

1. S. Yusuf, P. Sleight, and J. Pogue Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
2. G. Dagenais, J. Pogue, and K. Fox Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heat failure: a combined analysis of three trials Lancet 368 2006 581 588 (Pubitemid 44209181)
3. ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
4. TRANSCEND Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial Lancet 372 2008 1174 1183
5. G. Mazzaglia, E. Ambrosioni, and M. Alacqua Persistence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients Circulation 120 2009 1598 1605
6. A. Chobanian Impact of nonpersistence to antihypertensive therapy Circulation 120 2009 1558 1560
7. S. Simspon, D.T. Eurich, and S.R. Majumdar A meta-analysis of the association between persistence to drug therapy and mortality Br Med J 333 2006 15
8. Coronary Drug Project Research Group Influence of persistence to treatment and response of cholesterol on mortality in the coronary drug project N Engl J Med 303 1980 1038 1041
9. R.I. Horwitz, C.M. Viscoli, and L. Berkman Treatment persistence and risk of death after a myocardial infarction Lancet 336 1990 542 545 (Pubitemid 20278106)
10. J. Rasmussen, A. Chong, and D. Alter Relationship between persistence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction JAMA 297 2007 177 186 (Pubitemid 46089734)
11. S.J. Bennett, G.A. Huster, and S.L. Baker Characterization of the precipitants of hospitalization for heart failure decompensation Am J Crit Care 7 1998 168 174 (Pubitemid 128460530)
12. J.K. Ghali, S. Kadakia, and R. Cooper Precipitating factors leading to decompensation of heart failure: traits among urban blacks Arch Intern Med 148 1988 2013 2016
13. B.B. Granger, K. Swedberg, I. Ekman CHARM investigators Persistence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomized, controlled clinical trial Lancet 366 2005 2005 2011 (Pubitemid 41773375)
14. L. Osterberg, and T. Blaschke Persistence to medication N Eng J Med 353 2005 487 497
15. P.M. Ho, C.L. Bryson, and J.S. Rumsfeld Medication persistence: its importance in cardiovascular outcomes Circulation 119 2009 3028 3035
16. P.J. McDonnell, and M.R. Jacobs Hospital admissions resulting from preventable adverse drug reactions Ann Pharmacother 36 2002 1331 1336 (Pubitemid 34925265)
17. F.J. Penning-van Beest, F. Termorshuizen, and W.G. Goettsch Persistence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study Eur Heart J 28 2007 154 159
18. B.L. Senst, L.E. Achusim, and R.P. Genest Practical approach to determining costs and frequency of adverse drug events in a health care network Am J Health Syst Pharm 58 2001 1126 1132 (Pubitemid 32552897)
19. K. Teo, S. Yusuf, P. Sleight ONTARGET/TRANSCEND Investigators Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials Am Heart J 148 2004 52 61 (Pubitemid 38906646)
20. C.S. Stilley, S. Sereika, and M.F. Muldoon Psychological and cognitive function: predictors of persistence with cholesterol lowering treatment Ann Behav Med 27 2004 117 124 (Pubitemid 38364891)
21. R. Balkrishnan Predictors of medication persistence in the elderly Clin Ther 20 1998 764 771
22. A. Ammassari, M.P. Trotta, R. Murri AdICoNA Study Group Correlates and predictors of persistence to highly active antiretroviral therapy; overview of published literature J Acquir Immune Defic Synd 31 Suppl. 3 2002 S123 S127
23. S.H. Simspon, D.T. Eurich, and S.E. Majumdar A meta-analysis of the association between persistence to drug therapy and mortality Brit Med J 333 2006 15
24. C.R. Dormuth, A.R. Patrick, and W.H. Shrank Statin persistence and risk of accidents: a cautionary tale Circulation 119 2009 2051 2057
25. A.K. Gehi, S. Ali, and B. Na Self-reported medication persistence and cardiovascular events in patients with stable coronary artery disease: the heart and soul study Arch Intern Med 167 2007 1798 1803 (Pubitemid 47403069)
26. J.Y. Wu, W.Y. Leung, and S. Chang Effectiveness of telephone counseling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomized controlled trial Brit Med J 333 2006 552
27. S. Yusuf, J. Wittes, and J. Probstfield Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trial JAMA 266 1991 53 58
28. P. Rothwell Subgroup analysis in randomized controlled trials: importance, indications and interpretation Lancet 365 2005 176 186 (Pubitemid 40091809)
29. P. Rothwell, Z. Mehta, and S. Howard From subgroups to individuals: general principles and the example of carotid endarterectomy Lancet 365 2005 256 265 (Pubitemid 40138020)
30. U. Laufs, V. Rettig-Ewen, and M. Böhm Strategies to improve drug persistence Eur Heart J 32 2011 264 268